Mivacurium is a muscle relaxant that is used in hospitals and has been implicated in a number of homicides. A validated, sensitive method for the analysis of mivacurium and metabolites from biological specimens is presented here. Sample cleanup involves the precipitation of proteins with acetonitrile followed by analyte isolation using a commercially available solid-phase extraction column. Screening is performed by liquid chromatography with fluorescence detection, and confirmation is performed by liquid chromatography with tandem mass spectrometric detection. This method has been used to analyze dozens of forensic samples, including clinical specimens from living patients, as well as autopsy specimens from exhumed bodies.
Introduction
Mivacurium is a nondepolarizing neuromuscular blocking agent with a benzylisoquinolinium structure. It exists as a mixture of three stereoisomers: cis-trans, trans-trans, and cis-cis. The cis-trans and trans-trans isomers are approximately 10 times more potent than the cis-cis isomer (1, 2) . Compared to most other quaternary ammonium muscle blockers, mivacurium has a relatively short duration of action due to its rapid biotransformation by plasma cholinesterases (3, 4) . Its inactive metabolites are mivacurium esters (which exist as two isomers) and mivacurium alcohol (5) . Figure 1 shows the structure of mivacurium and its metabolites.
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E-mail: Madeline.Montgomery@ic.fbi.gov. focused on detecting these compounds in serum using liquid chromatography-fluorescence detection (LC-FLU) (3, 5, 7, 9, 10) . More recently, published procedures for quaternary ammonium compounds have focused on the use of LC-mass spectrometry (MS) or LC-MS-MS (8, (11) (12) (13) . The method presented in this paper uses both LC-FLU and LC-MS-MS for the unequivocal identification of mivacurium and its metabolites. Validation was achieved using whole blood, serum, urine, and tissue samples spiked with the compounds of interest. The procedure has been applied to numerous biological matrices.
Experimental

Reagents
Mivacurium and metabolites were provided by GlaxoSmithKline (Research Triangle Park, NC), and doxacurium chloride was from Glaxo Wellcome (Uxbridge, U.K.). Tubocuratine chloride, succinylcholine chloride, pancuronium bromide, and methanesulfonic acid were purchased from Sigma (St. Louis, MO). Succinylmonocholine chloride was obtained from U.S. Pharmacopeia (Rockville, MO). Maxi-Clean IC-RP SPE cartridges were purchased from Alltech (Deerfield, IL). Octanesulfonic acid was purchased from Waters Corporation (Milford, MA). All other solvents used were from Fisher (Fair Lawn, N J).
Sample preparation and extraction
Five micrograms of tubocurarine was added as the internal standard to 1-mL aliquots of biological fluid or 1-g portions of tissue homogenates (tissue homogenates were prepared by weighing out tissue samples, adding a volume of distilled water equal to twice the amount of tissue sample weighed out, and blending well in a blender or food processor). The final concentration of the internal standard, 5 IJg/mL of biological fluid, was required for adequate detection by LC-FLU. Acetonitrile (2 mL) was used to precipitate proteins while vortex mixing at high speed. Following centrifugation, the pellet produced in this process was discarded, and the supernatant reserved for further purification. The SPE cartridges were preconditioned with methanol (2.5 mL), followed by a 50:50 mixture of acetonitrile and water (2.5 mL). The supernatant liquid from the samples was applied to the SPE cartridges, and the acetonitrile was immediately collected, taken to dryness under nitrogen at 40~ and reconstituted with 100 IJL of the LC-MS mobile phase (40% acetonitrile/60% water/O.025% methanesulfonic acid). Samples were screened by LC-FLU and confirmed by LC-MS-MS.
LC-FLU instrumental conditions
The LC was a Hewlett-Packard series 1100 with a quaternary pump, autosampler, diode-array detector, and separate fluorescence detector. The LC was operated in a gradient mode using a chromatographic system adopted from other investigators (5, 8) . The mobile phase used in this system contained octanesulfonic acid for its ion pairing abilities. The initial mobile phase was 30% acetonitrile/70% 0.005M octanesulfonic acid at a flow rate of 2 mL/min. After 8 min, the mobile phase was changed in a linear gradient to 40% acetonitrile/60% 0.005M octanesulfonic acid. The analytical column used was a Lichrospher 60 RP-Select B (15 cm x 5 lJm x 4.6 mm) from Alltech. The optimal fluorescence excitation and emission wavelengths for mivacurium were determined experimentally to be 231 nm and 315 nm, respectively. Under the described chromatographic conditions, the mivacurium alcohol metabolite eluted first, with a retention time just under 2 rain; the internal standard eluted next, at approximately 2.5 rain; the two isomers of the mivacurium ester metabolite eluted between 4 and 5 min, with baseline resolution; and the three mivacurium isomers eluted between 9.5 and 11.5 min, also with baseline resolution. An example of an LC-FLU chromatogram of mivacurium and metabolites is shown in Figure 2 .
LC-MS-MS instrumental conditions
The LC was a Waters Alliance 2695 with autosampler, and the MS was a ThermoFinnigan LCQ iontrap with an electrospray interface and a metal electrospray needle. The LC mobile phase was 40% acetonitrile/60% water/0.025% methanesufonic acid, at a flow rate of 0.3 mL/min. The LC-MS-MS mobile phase contained methanesulfonic acid in place of octanesulfonic acid (used in the LC-FLU analysis) because of methanesulfonic acid's smaller size and increased volatility. As with the FLU analysis, the analytical column was a Lichrospher 60 RP-Select (15 cm x 5 ~m x 2.1 mm). Using the LC-MS-MS conditions, the elution order for mivacurium and its metabolites coincided with the LC-FLU method; however, the compounds eluted faster under these conditions, and baseline separation was not achieved for the isomers of mivacurium or its ester metabolites ( Figure 3) .
The MS was operated in MS-MS mode. Precursor ions were m/z 609 (for the internal standard), m/z 514 (for mivacurium), m/z 600 (for the mivacurium ester metabolites), and m/z 446 (for the mivacurium alcohol metabolite). Relative collision energies were chosen as those which produced the most signal while still allowing a small amount of the precursor ion to remain. The relative collision energies were as follows: internal standard = 31%, mivacurium alcohol metabolite = 32%, mivacurium ester metabolites = 36%, and mivacurium = 36%. Examples of product mass spectra are shown in Figure 4 . Of interest is that the mass-to-charge ratio of one of the main product fragments of mivacurium exceeds the mass-to-charge ratio of the precursor ion. This is a phenomenon sometimes observed when performing MS-MS on doubly charged precursor ions.
Results
Validation of LC-FLU procedure
The LC-FLU method was validated for quantitation using blank whole blood, serum, and urine spiked with known concentrations of mivacurium and its metabolites. Validation results from whole blood analyses are summarized in Table I . Lower limits of detection for mivacurium and its metabolites were determined by preparing serial dilutions of whole blood, serum, or urine spiked with the compounds. The amount of mivacurium or metabolite that produced a signal at least three times the signal produced by a blank biological extract was determined to be the lower detection limit for each analyte in the matrices studied. The detection limits in whole blood were determined to be 10 ng/mL for the mivacurium alcohol metabolite, 50 ng/mL for the mivacurium ester metabolites, and 50 ng/mL for the first eluting mivacurium isomer. The detection limits in serum were determined to be 10 ng/mL for the mivacurium alcohol metabolite, 250 ng/mL for the mivacurium ester metabolites, and 500 ng/mL for the first eluting mivacurium isomer. The detection limits in urine were determined to be 10 ng/mL for the mivacurium alcohol metabolite, 25 ng/mL for the mivacurium ester metabolites, and 50 ng/mL for the first eluting mivacurium isomer. It should be noted that there was an interfering peak in blank urine that eluted close to the mivacurium alcohol metabolite using the LC-FLU chromatographic conditions; however, this interference was readily resolved by with the LC-MS-MS assay. The relatively higher detection limits in serum for the later eluting compounds were attributed to interferences that elevated the instrumental baseline.
The limit of quantification was determined in whole blood for each analyte by choosing the concentration at which the precision [measured as the coefficient of variation (CV)] was less than 15%. The limits of quantitation for mivacurium and its metabolites were all 100 ng/mL.
The between-run precision of the method was determined by analyzing whole blood samples spiked at 100 and 500 ng/mL of each analyte on four separate days against fresh calibration Figure 3 . Chromatograms for mass spectral data of mivacurium and metabolites. Extracted blood sample spiked to 100 ng/mL mivacurium and metabolites. curves. The CVs for those determinations were under 15% for all analytes at each level. Extraction recovery was evaluated by comparing the average peak area of three extracted whole blood spikes to the average peak area of three unextracted standards of mivacuriurn and its metabolites at two concentrations (100 and 500 ng/mL). Recovery of the mivacurium alcohol metabolite, the mivacurium ester metabolite isomers, and the first eluting mivacurium isomer averaged 65%, 56%, and 75%, respectively. True accuracy of the method was not evaluated because our laboratory had only one available source of mivacurium and metabolites. Nonetheless, the three analytes were quantitated out of whole blood on four separate days, producing average accuracies under 10% of the target values. Injection standards of doxacurium, succinylcholine, succinylmonocholine, and pancuronium were analyzed using the LC-FLU method and were found not to interfere with the detection and quantitation of mivacurium and its metabolites. Furthermore, other than the urine interference reported, no other extraneous peaks were observed in blank matrices at the retention times of interest.
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Validation of LC-MS-MS procedure
The LC-MS-MS method was used strictly for qualitative confirmation of the LC-FLU results. Therefore only the qualitative performance characteristics of the LC-MS-MS method were determined. The detection limits were determined for whole blood, serum, and urine using the same criteria as had been used for the LC-FLU method. The detection limits for extraction from both whole blood and serum were as follows: 10 ng/mL for the mivacurium metabolite, 10 ng/mL for the mivacurium ester metabolites, and 50 ng/mL for mivacurium. The detection limits from urine were ]0 ng/mL for the mivacurium alcohol metabolite, 10 ng/mL for the mivacurium ester metabolites, and 25 ng/mL for mivacurium. In order to assess the selectivity of the assay, five random autopsy liver samples (taken from patients with no history of mivacurium exposure) were extracted and analyzed by LC-MS-MS. Mivacurium and its metabolites were not detected in any of the five liver samples.
In order to assess the effects of the embalming process on the assay, "embalmed" kidney and heart samples were prepared in house. A kidney sample and a heart sample from the autopsy of an individual (known to have no previous exposure to mivacurium) were soaked for 36 h in a commercial embalming fluid containing formaldehyde and methanol. Homogenates were prepared from these embalmed tissues, which were then spiked with mivacurium and metabolites at 1 lJg/g of homogenate. When the homogenates were extracted and analyzed by LC-MS-MS, mivacurium and metabolites were detected. 
Application of the method
The described method was applied to the analysis of samples from 10 exhumed bodies of individuals suspected to have been administered mivacurium in a serial homicide investigation. Fresh autopsy specimens were not available from these individuals; only autopsy samples obtained after the exhumation were used. To determine the best specimens to screen for potential mivacurium administration, as many samples as possible were analyzed from the first four bodies. Table II provides a summary of the results obtained from the first four exhumed bodies. As shown in the table, blood clots were collected from several of the exhumed bodies, presumably because the blood was not completely removed during the embalming process. It should be noted that quantitative results are not provided, as this laboratory does not typically quantitate drugs or poisons that are identified in samples obtained from exhumed bodies. As discussed later, the stability of mivacurium in solution also became a critical issue for quantitative analysis.
When the next six exhumed bodies were received in the laboratory, the toxicological analyses focused on blood clots and urine as these specimens consistently allowed for the determination of mivacurium and its metabolites in the initial bodies that were examined.
This procedure was also used to analyze several clinical specimens. These specimens were from four individuals who had gone into respiratory arrest under suspicious circumstances while in the hospital. During this period of time, several vials of mivacurium were discovered to be missing from the hospital pharmacy. According to hospital records, these patients were not administered mivacurium. Limited volumes of serum were availab]e from the four patients, and whole blood was also available from one. Mivacurium alcohol was identified in the serum taken from all four individuals, as well as in the one whole blood clinical specimen. The ester metabolite of mivacurium was identified in serum from one individual. Parent mivacurium was not identified in any of these specimens. A serum sample collected from one of the individuals four days after respiratory arrest took place was negative for mivacurium and metabolites. A separate serum sample collected from another of the individuals four months after the suspected unauthorized mivacurium exposure took place was also negative for mivacurium and its metabolites.
Discussion
A rapid and simple method for the analysis of mivacurium and its metabolites has been developed and applied to a wide variety of biological samples. Simple clean-up of samples using acetonitrile to precipitate proteins and SPE cartridges to filter the resulting acetonitrile extract was sufficient for most matrices tested. The exception was with brain samples in which the internal standard was not recovered. Additionally, by LC-FLU, the detection limits for mivacurium and its ester metabolites from serum were much higher than from urine or whole blood. This was due to interferences in serum that resulted in an increasingly elevated baseline as the chromatogram progressed, which in turn lowered the resolution of later eluting peaks. These serum components did not interfere with the LC-MS-MS assay.
When available, urine and blood clots appeared to be the best specimens to test from exhumed bodies. Mivacurium metabolites were identified in all blood and urine samples collected from exhumed bodies that had at least one corresponding tissue with mivacurium and/or metabolites identified.
Instability of mivacurium in aqueous solution was noted during our validation process. When the mivacurium solution was initially prepared, no degradation products were detected in the preparation by LC-MS. However, after only two days of storage at 4~ the metabolites were identified in the solution, presumably as hydrolysis products. Because of this phenomenon, and the limited amount of pure mivacurium available, quantitative results were not reported for the forensic samples analyzed. Furthermore, given the history of no documented previous exposure to mivacurium, the investigation only required a qualitative determination of its presence.
In many of the biological specimens, the mivacurium alcohol metabolite was the only mivacurium-related compound identified. When any of the three analytes was identified, mivacurium alcohol was always one of them. This is likely due to the detection limits for this metabolite being among the lowest of the three analytes and mivacurium's rapid metabolism in the body (3,4).
The SPE utilized in this procedure was simple and sufficient to clean up biological samples, including tissue homogenates, for LC-FLU and LC-MS-MS analysis. The LC-MS-MS technique gave unique product spectra for mivacurium and its metabolites allowing for their unequivocal identification.
This method has been applied to the analysis of numerous samples from individuals believed to have been administered mivacuriurn. Furthermore, through simple alterations to the tandem mass spectral detection parameters, this method can be applied to the analysis of other quaternary ammonium compounds.
